Keyphrases
Acute Myeloid Leukemia
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Renaissance
100%
Therapeutic Concepts
100%
Maintenance Therapy
100%
Leukemia Patients
50%
Remission
50%
Patient Selection
50%
Intensive Chemotherapy
50%
Overall Survival Benefit
50%
Clinical Trials
25%
Randomized Trial
25%
Therapeutic Approaches
25%
Overall Survival
25%
Hypomethylating Agents
25%
Sorafenib
25%
Cause of Death
25%
New Therapeutics
25%
Targeted Agents
25%
Personalized Therapy
25%
Leukemic Cells
25%
Patient Safety
25%
Induction Chemotherapy
25%
Relapse-free Survival
25%
FLT3 Inhibitor
25%
CC-486
25%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Hematopoietic Cell
100%
Maintenance Therapy
100%
Overall Survival
75%
Patient Selection
25%
Recurrence Free Survival
25%
Sorafenib
25%
Hypomethylating Agent
25%
Clinical Trial
25%
Induction Chemotherapy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Chemotherapy
75%
Overall Survival
75%
Remission
50%
Clinical Trial
25%
Recurrence Free Survival
25%
Sorafenib
25%